Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H
Department of Obstetrics and Gynecology, Saga Medical School, Japan.
Gynecol Oncol. 1998 Jun;69(3):220-5. doi: 10.1006/gyno.1998.5023.
The aim of this study was to evaluate the prognostic significance of steroid hormone receptors in endometrial carcinoma using immunohistochemical staining for progesterone receptor (PR) and estrogen receptor (ER).
We evaluated the correlation between PR/ER immunohistochemistry and age, clinical stage, tumor grade, myometrial tumor invasion, and disease-free survival in a series of 92 cases of endometrioid adenocarcinoma.
Fifty (54.4%) endometrial carcinomas were PR-positive and 44 (47.8%) were ER-positive. PR immunohistochemistry of endometrial carcinoma was statistically correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage (I, II vs III, IV, P = 0.001), FIGO grade (G1 vs G2 vs G3, P = 0.007), the depth of myometrial tumor invasion (< or = 1/2 vs > 1/2, P = 0.006), and disease-free survival (living vs dead, P = 0.0025). In contrast, ER immunohistochemistry had significant correlations with the depth of myometrial tumor invasion (P = 0.026) and disease-free survival (P = 0.032). Multivariate analysis of PR/ER immunohistochemistry, stage, grade, and myometrial invasion showed that the PR immunohistochemistry was a significant prognostic factor for survival (P = 0.026).
PR/ER immunohistochemistry was significantly related to survival and PR immunohistochemistry appeared to be the most reliable means for predicting survival in endometrioid adenocarcinoma of the endometrium, independent of other clinicopathological parameters.
本研究旨在通过对孕激素受体(PR)和雌激素受体(ER)进行免疫组化染色,评估类固醇激素受体在子宫内膜癌中的预后意义。
我们评估了92例子宫内膜样腺癌患者中PR/ER免疫组化与年龄、临床分期、肿瘤分级、肌层肿瘤浸润及无病生存期之间的相关性。
50例(54.4%)子宫内膜癌PR阳性,44例(47.8%)ER阳性。子宫内膜癌的PR免疫组化与国际妇产科联盟(FIGO)分期(I、II期与III、IV期,P = 0.001)、FIGO分级(G1、G2与G3级,P = 0.007)、肌层肿瘤浸润深度(≤1/2与>1/2,P = 0.006)及无病生存期(存活与死亡,P = 0.0025)具有统计学相关性。相比之下,ER免疫组化与肌层肿瘤浸润深度(P = 0.026)及无病生存期(P = 0.032)具有显著相关性。对PR/ER免疫组化、分期、分级及肌层浸润进行多因素分析显示,PR免疫组化是生存的重要预后因素(P = 0.026)。
PR/ER免疫组化与生存显著相关,且PR免疫组化似乎是预测子宫内膜样腺癌生存的最可靠方法,独立于其他临床病理参数。